Arrowhead Pharmaceuticals
ARWRPharmaPasadena, California, United States · Est. 1989
Arrowhead Pharmaceuticals is a biopharmaceutical company developing RNA interference therapeutics for treating diseases with high unmet medical needs.
8
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
11
Indications↗
Distinct diseases across all programs
59
Clinical Trials↗
All sponsored trials (all statuses)
5
Orange Book Patents
Across 1 drug with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
8 drugs in development
Phase 33
Phase 21
Preclinical4
By Therapeutic Area
top 3
Metabolic & Endocrine
675%
Respiratory
113%
Neurology
113%
R&D Momentum
56/100
Pipeline Velocity
22/100
Trial Completion Rate
58/100
Pipeline Concentration
59/100
Pipeline Freshness
83/100
Strategic Signals
- ↗Active in Respiratory but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Jul 14, 2026
Recruiting
Phase 1/2a, Double-blind, Placebo-controlled, Single and Multiple Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of ARO-DIMERPA in Adult Subjects With Mixed Hyperlipidemia
Jul 9, 2026
Recruiting
A Phase 1/2A Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-ALK7 in Adult Volunteers With Obesity With and Without Type 2 Diabetes Mellitus
Earlier
Jun 30, 2026TrialA Phase 1 Placebo-Controlled Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-ATXN2 in Adult Subjects With Spinocerebellar Ataxia Type 2
Jun 27, 2026TrialDouble-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Hypertriglyceridemia
Jun 27, 2026TrialDouble-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study)
Jun 27, 2026TrialA Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-INHBE in Adult Volunteers With Obesity With and Without Diabetes Mellitus
Jun 24, 2026TrialA Randomized, Double-blind, Placebo-controlled Phase 2a Study of ARO-RAGE Inhalation Solution to Assess Efficacy on Small Airway Dysfunction in Allergen-induced Mild Asthma
Jun 24, 2026TrialA First-In-Human Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ARO-033 in Adult Participants
4 more events
Jun 24, 2026TrialA Phase 1/2a Placebo-Controlled Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease
Mar 1, 2026TrialStudy of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia
Nov 18, 2025FDARedemplo — REDEMPLO
Jun 17, 2025TrialA Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
Details
Company Info
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
CEOVipin Nair
Founded1989
HQPasadena, California, United States
Websitearrowheadresearch.com
LinkedInCompany Page
Therapeutic Focus
Infectious DiseaseImmunologyOncologyNeurologyOtherRespiratoryGastroenterologyMetabolic & EndocrineRare Disease
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Metabolic & Endocrine
Neurology
Metabolic & Endocrine
Diabetes Mellitus
ARO-INHBEPhase 2
Hyperlipidemia
ARO-DIMERPAPhase 2
Hyperlipidemia; Mixed
ARO-DIMERPAPreclinical
Hypertriglyceridemia
RedemploPhase 3
Plozasiran InjectionPhase 3
Neurology
Alzheimer Disease
ARO-MAPT-SCPreclinical
Respiratory
Lung Disease
ARO-RAGEPhase 2
Regulatory
Regulatory Timeline
20251 event
FDANov 18
Redemplo — REDEMPLO
Application NDA219947 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)